| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 06 Nov 2026 |
8-K: Results of Operations and Financial Condition
Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 |
| 12 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 07 Aug 2026 |
8-K: Results of Operations and Financial Condition
Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 |
| 04 Jun 2026 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
SECTION 1.01. Registered Office. The registered office of the corporation shall be Corporation Service Company, 2711 Centerville Road, Suite 400, City of Wilmington, County of New Castle, State of Delaware until otherwise established by ... |
| 27 May 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Minerva Neurosciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened |
| 06 Apr 2026 |
8-K: Other Events
Minerva Neurosciences, Inc. (the “Company”) today announced that the expected date for the Company’s 2026 annual meeting of stockholders (the “Annual Meeting”) is June 3, 2026, which is more than 30 days before the one-year anniversary o... |
| 02 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure +1 more
Mind-NRG SARL incorporated and registered in Switzerland whose registered office is at Cours de Rive 10, 1204 Geneva, Switzerland (Company / we / us / our) |
| 11 Mar 2026 |
8-K: Results of Operations and Financial Condition
Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027 |
| 03 Feb 2026 |
8-K: Regulation FD Disclosure; Other Events
As previously announced, Minerva Neurosciences, Inc. (the “Company”) is hosting a virtual key opinion leader (“KOL”) event on Tuesday, February 3, 2026 at 10:30 a.m. Eastern Time. The presentation to be used during the event will be made... |
| 22 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan’s Available Res... |
| 19 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
THIS CONSULTING AGREEMENT (the “Agreement”) by and between Minerva Neurosciences, Inc (“Client”) and Inderjit Kaul, (“Consultant”) is effective as of November 14, 2025 (the “Effective Date”). |
| 22 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This Securities Purchase Agreement (this “Agreement”) is dated as of October 21, 2025, by and between MINERVA NEUROSCIENCES, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each,... |
| 19 Mar 2025 |
8-K: Other Events
On March 17, 2025, Minerva Neurosciences, Inc. (the “Company”) was formally notified that the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) determined that the Company has regained compliance with Nasdaq L... |
| 13 Jan 2025 |
8-K: Other Events
As previously disclosed, on April 10, 2024, Minerva Neurosciences, Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 31 consecutive business days, the Company... |
| 05 Dec 2024 |
8-K: Submission of Matters to a Vote of Security Holders
The results of matters submitted to a stockholder vote at the Annual Meeting of Stockholders of Minerva Neurosciences, Inc. (the “Company”) held on December 5, 2024 (the “2024 Annual Meeting”) are as follows: |
| 11 Oct 2024 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
As previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on April 12, 2024, on April 10, 2024, Minerva Neurosciences, Inc. (the “Company”) received written notice from The Nasdaq Stock Mar... |
| 16 Sep 2024 |
8-K: Other Events
On September 14, 2024, the board of directors of Minerva Neurosciences, Inc. (the “Company”) set the expected date for the Company’s 2024 annual meeting of stockholders (the “Annual Meeting”) for December 5, 2024, which is more than 30 d... |
| 30 May 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Loading...